Articles examining preclinical findings, human studies, trial design, endpoints, limitations and the current state of clinical evidence.
A plain-English guide to tirzepatide’s GIP and GLP-1 receptor design, the clinical evidence, unresolved questions and evidence-transfer limits.
Tirzepatide Explained: Dual-Receptor Signalling and the Evidence Behind the Medicine Read More »
A plain-English guide to semaglutide, longer-lasting GLP-1 signalling, laboratory and human evidence, and where research findings do not transfer.
Semaglutide Explained: GLP-1 Signalling and What the Evidence Really Tests Read More »
A plain-English guide to tesamorelin, GHRH signalling, the human evidence, regulatory limits and the boundaries of what current research can establish.
Tesamorelin Explained: GHRH Signalling, Human Trials and Regulatory Limits Read More »
Evidence reviewed: 7 August 2026Author: ExtolX Editorial Team This is an educational overview of published research, not medical advice. Retatrutide, also known as LY3437943, is an experimental peptide developed by Eli Lilly. It has attracted attention because one molecule is designed to activate three hormone-receptor systems connected with appetite, blood sugar and the way the
Retatrutide Explained: How Triple-Receptor Research Works Read More »
Evidence reviewed: 21 August 2026Author: ExtolX Editorial Team This is an educational overview of published research, not medical advice. Semax is a laboratory-made peptide based on a small part of the natural hormone ACTH. Researchers have studied it in cells, animals and some regional clinical settings, but the accessible human evidence is much narrower than
Semax: ACTH-Derived Peptide Research and Evidence Gaps Read More »
Evidence reviewed: 21 August 2026Author: ExtolX Editorial Team This is an educational overview of published research, not medical advice. Selank is a laboratory-made peptide derived from tuftsin, a natural immune-system peptide. Most published work examines signalling and behaviour in laboratory or animal models; the available human research is too limited to support broad claims about
Selank: Tuftsin-Derived Peptide Research and Human Evidence Read More »
PT-141 is the development name associated with bremelanotide, but approval applies to a specific finished medicine—not every material sharing the peptide name.
PT-141 Explained: Bremelanotide Research and the Limits of Product Equivalence Read More »
Evidence reviewed: 21 August 2026Author: ExtolX Editorial Team This is an educational overview of published research, not medical advice. Melanotan II is a laboratory-made peptide based on alpha-melanocyte-stimulating hormone. Early human studies reported biological effects, but they were small and also recorded unwanted effects. They do not provide a complete account of safety or support
Melanotan II: Melanocortin Biology, Early Human Studies and Safety Questions Read More »
CJC-1295 No DAC and ipamorelin act through different upstream receptors. Learn why the rationale does not establish synergy or clinical benefit.
CJC-1295 No DAC + Ipamorelin Explained: Two Pathways, One Evidence Gap Read More »